文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

大型单中心HIV队列中两药方案使用及组成的相关因素

Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究回顾性分析巴塞罗那医院诊所2020年1月随访的HIV成人患者,比较两药方案(2DR)与三药方案(3DR)的使用情况,发现既往多次病毒学失败、耐药突变、AIDS病史、当前方案使用时间更长、总胆固醇或甘油三酯更高及基线血红蛋白更低与2DR使用独立相关。2DR多包含整合酶抑制剂或/和蛋白酶抑制剂,低HDL胆固醇与整合酶抑制剂使用相关,既往AIDS、耐药突变及低CD4/CD8比值与蛋白酶抑制剂使用相关。

要点

  • 既往病毒学失败≥2次、耐药突变和AIDS病史与2DR使用独立相关。
  • 代谢指标(高总胆固醇/甘油三酯、低HDL)和低基线血红蛋白与2DR选择相关。
  • 2DR中整合酶抑制剂与低HDL相关,蛋白酶抑制剂与既往AIDS和耐药相关。

核心结论

  • 在该大型单中心HIV队列中,更差的心代谢状态或更多存档耐药分别是2DR中包含整合酶抑制剂或蛋白酶抑制剂的关键因素。

研究设计与样本

  • 回顾性分析巴塞罗那医院诊所2020年1月前瞻性随访的所有接受3DR或2DR的HIV成人患者。
  • 使用逻辑回归模型评估与2DR使用相关的因素,控制年龄、性别和HIV诊断年份。

主要发现

  • 3432例(88%)接受3DR,463例(12%)接受2DR。
  • 最终调整模型中,既往病毒学失败≥2次、既往耐药突变、既往AIDS诊断、当前方案使用时间更长、总胆固醇或甘油三酯更高及基线血红蛋白更低是2DR的独立相关因素。
  • 大多数2DR包含整合酶抑制剂或/和蛋白酶抑制剂。
  • 低HDL胆固醇与2DR中包含整合酶抑制剂独立相关;既往AIDS、既往基因型耐药突变和低CD4/CD8比值与包含蛋白酶抑制剂独立相关。

临床怎么用

  • 对于有多次病毒学失败、耐药突变或AIDS病史的HIV患者,可考虑使用包含蛋白酶抑制剂的2DR。
  • 对于心代谢状态较差(如低HDL胆固醇)的患者,2DR中可考虑包含整合酶抑制剂。

局限性

  • 本研究为单中心回顾性分析,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to assess the clinical characteristics associated with the use of two-drug regimens (2DRs) and the factors associated with specific antiretrovirals in 2DRs in a large single-centre HIV cohort. METHODS: Retrospective analysis of demographics, HIV characteristics and AIDS events, antiretroviral prescription, virological failure and genotypic resistance testing, and laboratory results from all adult people with HIV (PWH) prospectively followed at the Hospital Clinic of Barcelona who were receiving a 3DR or a 2DR in January 2020. We assessed factors associated with the probability of receiving 2DRs relative to three-drug regimens (3DRs) using a logistic regression model, controlling for age, sex and year of HIV diagnosis. The same methodology was applied to identify factors associated with the prescription of integrase inhibitor-based regimens or PI-based regimens among PWH receiving 2DRs. RESULTS: There were 3432 (88%) PWH receiving 3DRs and 463 (12%) receiving 2DRs. In the final adjusted model, ≥2 previous virological failures, previous resistance mutations, previous AIDS diagnosis, longer time on current regimen, higher total cholesterol or triglycerides and lower baseline haemoglobin were independent factors associated with 2DRs. The majority of 2DRs included an integrase inhibitor or/and a PI. We identified independent factors associated with the inclusion of integrase inhibitors (lower HDL cholesterol) or PIs (prior AIDS, prior genotypic resistance mutations and lower CD4/CD8 ratio) in the 2DR. CONCLUSIONS: In this large single-centre HIV cohort, a worse cardiometabolic status or more archived resistance were key factors associated with inclusion of integrase inhibitors or PIs, respectively, in 2DRs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. de Lazzari E, Gonzalez-Cordon A, Inciarte A, et al. Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort. J Antimicrob Chemother. 2021. PMID: 34293162. doi:10.1093/jac/dkab261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。